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Objective: We attempted to determine the association between a G/A polymorphism 
at position 158 of the prostate-specific antigen (PSA) gene and the risk of prostate 
cancer in Taiwanese men.
Materials and Methods: We genotyped 149 prostate cancer patients and 176 healthy 
controls. Logistic regression was used to estimate the odd ratios (ORs) and confi-
dence intervals (CIs).
Results: The G allele was more frequent than the A allele in both cases and in controls. 
The A allele was not associated with a significantly  higher risk of prostate cancer (odds 
ratio [OR] = 1.17, confidence interval = 0.78–1.76). GA (OR = 1.18) and AA (OR = 1.19) 
genotypes were not associated with a significantly higher risk of prostate cancer. 
In an analysis by disease aggressiveness, aggressive disease had a higher OR than 
that for nonaggressive disease (1.38 vs. 0.77); however, these associations were not 
statistically significant.
Conclusions: No association was found between G/A polymorphism and the risk of 
prostate cancer. Larger studies are necessary to determine whether the A allele is 
associated with aggressive prostate cancer.
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1.  Introduction
Prostate cancer is the fifth most common type of cancer, 
and it is the seventh leading cause of cancer deaths in 
Taiwanese men.1 Its incidence in 2007 was 23.5 per 
100,000, and the mortality rate was 7.4 per 100,000.
Age, race, genetics, diet, environment, infectious 
agents, physical activity, sexual activity, smoking, and 
having had a vasectomy are reported to be potential risk 
factors for prostate cancer.
The association between genetic polymorphisms 
and prostate cancer has been extensively studied. 
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Polymorphisms at the 158 position of the prostate-
specific antigen (PSA) gene are proposed to be associated 
with an increased risk of prostate cancer.2 Therefore, we 
conducted a case control study to verify this occurrence 
in a Taiwanese population.
2. Materials and Methods
Peripheral blood lymphocytes were collected from 149 
prostate cancer patients and 176 healthy controls from 
Mackay Memorial Hospital in Taiwan. Demographic and 
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clinical data were obtained from medical records. Men 
with an ethnicity other than Han Chinese were excluded 
from this study. This study was approved by the Institutional 
Review Board of Mackay Memorial Hospital, and written 
informed consent was obtained from all study subjects.
A 5 mL sample of peripheral blood was obtained from 
each prostate cancer patient and control subject. Buffy 
coat samples were prepared immediately and stored at 
–80°C until extraction of genomic DNA. Genomic DNA 
was obtained by conventional phenol/chloroform ex-
traction, followed by ethanol precipitation, and stored 
at –20°C until used for genotyping by polymerase chain 
reaction-restriction fragment length polymorphism.
The NheI restriction enzyme was used to distinguish 
the allele of the G/A polymorphism at position 158 in the 
promoter region of the PSA gene.2 Amplification of the 
polymorphic site was performed using a forward primer 
(5’-TTG TAT GAA GAA TCG GGG ATC GT-3’) and a reverse 
primer (5’-TCC CCC AGG AGC CCT ATA AAA-3’). Polymerase 
chain reaction-restriction fragment length polymorphism 
was carried out with 20 ng of genomic DNA and 10 pmoL 
of each primer in a 20-μL reaction volume containing 
2 mM MgCl2 under the following conditions: 93°C for 
10 minutes, followed by 35 cycles of 94°C for 1 minute, 
59°C for 1 minute, and 72°C for 40 seconds, with a final 
cycle of 72°C for 10 minutes. Digestion of a 7-μL aliquot 
was conducted with 1.5 units of NheI restriction enzyme 
(New England Biolabs, Beverly, MA, USA) in 1.5 μL of 
10× bovine serum albumin and 6 μL of water at 37°C for 
over 3 hours, and the fragments were then separated on 
a 2.5% agarose gel. The three distinct banding patterns 
observed represented the three possible genotypes: AA 
(300 bp), AG (150 and 300 bp), and GG (150 bp).
The allelic and genotypic frequencies of the PSA gene 
were then determined. Statistical methods  were used to 
determine the significance of the differences of the allele 
and genotype frequencies between the case and control 
groups. Logistic regression models were used to estimate 
the odds ratios (ORs) and their corresponding 95% confi-
dence intervals (CIs) between the case and control groups. 
Patients with a PSA value > 20 ng/mL, clinical stage ≥ T3, or 
a Gleason score of ≥ 8 were classified as having aggres-
sive disease. In the calculation of the risk allele, ORs in 
aggressive and nonaggressive disease, the trends across the 
wild-type homozygote, variant heterozygote, and variant 
homozygote were tested by logistic regression, and a vari-
able with respective values of 0, 1, and 2 was used. The 
Statistical Package for the Social Sciences, version 11 (SPSS, 
Chicago, IL, USA) was used for the statistical analysis.
3.  Results
We recruited 149 prostate cancer patients and 176 con-
trols. The mean (SD) age of the prostate cancer patients 
was 75.48 ± 5.31 years, and the mean age of the control 
group was 72.79 ± 7.01 years (p < 0.01). The mean Gleason 
score of the prostate cancer patients was 6.84 ± 1.56.
The allelic frequencies of the G and A alleles at posi-
tion 158 of the PSA gene are shown in Table 1. The fre-
quency of the G allele was higher than that of the A 
allele in both the prostate cancer (81.9% vs. 18.1%) and 
control groups (84.1% vs. 15.9%). The control group had 
a slightly higher frequency of the G allele than the pros-
tate cancer group (84.1% vs. 81.9%). The A allele ap-
peared to be associated with a higher risk of prostate 
cancer (OR = 1.17), but this association was not statistically 
significant (CI = 0.78–1.76).
The genotypic frequencies of the GG, GA, and AA 
single nucleotide polymorphisms are shown in Table 1. 
The control group had a slightly higher frequency of the 
GG genotype (71.6% vs. 67.1%) than prostate cancer 
cases. The GA (OR = 1.18) and AA genotypes (OR = 1.19) 
appeared to be associated with a higher risk of prostate 
cancer compared with the GG genotype.  However, these 
associations were not statistically significant (GA, CI = 
0.71–1.96; AA, CI = 0.35–4.08). Because the number of 
subjects with the AA genotype was relatively small, sub-
jects with the GA and AA genotypes were pooled together 
and compared with those with the GG genotype. However, 
the increased risk of prostate cancer (OR = 1.18) was not 
statistically significant (CI = 0.72–1.92). The PSA level ap-
peared to be slightly higher in the GG genotype group 
(382.2 ± 1581.5 ng/mL) compared with that in the GA and 
AA genotype groups (301.2 ± 697.0 ng/mL); however, this 
difference was not statistically significant (p = 0.74).
Table 1  Allelic and genotypic frequencies of prostate-specific antigen (PSA) gene polymorphism in prostate cancer patients 
and controls*
PSA gene 158 G/A polymorphism Cases (n = 149) Controls (n = 176) OR (95% CI)
G-allele 244 (81.9) 296 (84.1) 1.00 (reference)
A-allele 54 (18.1) 56 (15.9) 1.17 (0.78–1.76)
GG 100 (67.1) 126 (71.6) 1.00 (reference)
GA 44 (29.5) 44 (25.0) 1.18 (0.71–1.96)†
AA 5 (3.4) 6 (3.4) 1.19 (0.35–4.08)†
GA + AA 49 (32.9) 50 (28.4) 1.18 (0.72–1.92)†
*Data presented as n (%) or OR (95% CI); †age-adjusted OR. PSA = prostate-specific antigen; OR = odds ratio; CI = confidence interval.
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With regard to disease aggressiveness, aggressive 
disease appeared to have a higher OR than nonaggres-
sive disease (1.38 vs. 0.77) (Table 2). Even though these 
associations were not statistically significant, the risk al-
lele appeared to be associated with more aggressive 
prostate cancer.
4.  Discussion
The PSA gene is a kallikrein-like protease synthesized by 
luminal epithelial cells of the prostate.3 PSA expression 
is regulated by androgens via the androgen receptor. 
Androgen response element-I is one of three androgen 
response elements identified in the PSA gene promoter. 
A single nucleotide polymorphism, an adenine to guanine 
substitution at position 158 in androgen response element-
I, has been described,4 and Xue et al. proposed that the 
androgen receptor binds the A and G alleles with differing 
affinities, thereby influencing prostate cancer risk.2
Several studies have investigated the relationship 
between this polymorphism and the risk of prostate 
cancer with contradictory results. While several studies 
have shown an association between the GG genotype 
and advanced prostate cancer at the time of diagnosis,2,5–7 
our results showed that the GG genotype was not asso-
ciated with advanced disease.
Some studies have shown that the GG genotype con-
fers an increased risk of prostate cancer,2,7 while others 
have reported no significant association;8–10 one study 
even suggested that the G allele has a protective effect 
against prostate cancer.5
In a study of a Taiwanese population, Chiang et al. 
reported significantly greater frequencies of the G allele 
(87.3% vs. 61.9% in the controls) and the GG genotype 
(78.7% vs. 61.9% in the controls) in prostate cancer 
patients.11 However, our study is not in agreement with 
those results, since greater frequencies of the G allele 
and GG genotype were found in the controls. However, 
our findings were not statistically significant. The differ-
ence between studies is unknown, but we propose that 
the association between this polymorphism and the risk 
of prostate cancer in an ethnic Han Chinese population 
may be weaker than previously thought.
Allelic frequencies may also vary according to ethnicity. 
The A and G alleles are reported to occur in equal frequen-
cies in Caucasian and African-American populations.4 
A Japanese study by Wang et al. reported that the A 
allele is less common (22% vs. 78% for the G allele),8 and 
a Taiwanese study by Chiang et al. showed that the A 
allele is present in only 13% of prostate cancer patients.11 
Our study results are consistent with this finding as the 
A allele frequency in prostate cancer patients was calcu-
lated to be 18%.
The main limitations of this study are that the PSA 
level was not obtained in control subjects and that age-
matching was not performed between controls and cases. 
Even though an elevated PSA level could also be caused 
by infection, benign prostatic enlargement, or instrumen-
tation, a markedly elevated PSA may have warranted a 
pathological examination to rule out the presence of 
prostate cancer. Therefore, it is possible that some of the 
subjects in the control group may have harbored prostate 
cancer. The control subjects were approximately 2 years 
younger than the prostate cancer cases. The incidence of 
prostate cancer increases with age, and it is possible that 
some of the subjects originally grouped as the controls 
may have developed prostate cancer as they grew older.
5.  Conclusions
In this study, the PSA 158 A/G polymorphism was not 
found to be associated with a risk of prostate cancer in a 
Taiwanese population. The frequency of the A allele in 
prostate cancer patients is lower in Asian than in Caucasian 
and African-American populations. A larger study is re-
quired to determine whether the A allele is associated 
with aggressive prostate cancer.
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